Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Endo Pharma Files Amendment To Its Citizen Petition With FDA - Quick Facts

RELATED NEWS
Trade ENDP now with 

Endo Pharmaceuticals (ENDP: Quote) said it has filed an amendment to its Citizen Petition with the FDA calling on FDA to publicly address numerous concerns raised by Endo and other experts about approval requirements for generic versions of LIDODERM, or lidocaine patch 5%.

The amended Citizen Petition highlights the growing scientific and regulatory support for requiring generic manufacturers to conduct comparative clinical endpoint studies to demonstrate bioequivalence to locally acting topical products like LIDODERM. The amended Citizen Petition also raises several new issues that need to be resolved before FDA approves a generic formulation of LIDODERM.

The amended Citizen Petition asks FDA to address the repeated public statements by scientific experts and FDA officials that pharmacokinetic studies, which measure the level of a drug in the bloodstream, have not yet been validated as a bioequivalence method for locally acting topical drugs like LIDODERM.

The amendment also points out that FDA has not produced any evidence indicating that pharmacokinetic studies are sufficiently sensitive to determine whether a proposed generic product will replicate LIDODERM's clinical effect.

Ivan Gergel, Executive Vice President of R&D and Chief Scientific Officer at Endo, said, "..FDA must publicly address the many unanswered questions from the original petition, as well as the additional concerns raised in this amendment, before taking any formal steps toward the approval of a generic version of LIDODERM."

Register
To receive FREE breaking news email alerts for Endo International plc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.